Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Calliditas is aiming to raise new funding in an IPO and listing on Nasdaq Sweden to support late-stage clinical development and commercialization of its Berger's disease candidate, and studies in additional indications.
Latest From Companies
ViiV CEO predicts strong pipeline and two-drug strategy will reinforces group's HIV market position and put it ahead of Gilead by the mid-2020s.
In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to Spectrum. Using IP from UCLA, Bloom launches with focus on neuroprotective epilepsy therapies.
Chairman says Freeline's series B financing gives it adequate funds for Phase I/II trials in hemophilia B and entry into Fabry disease.
Novartis immunology chief Eric Hughes tells Scrip a wealth of data is showing that early treatment with Cosentyx can prevent the structural changes that lead to lack of mobility in ankylosing spondylitis and psoriatic arthritis patients.
ViiV Healthcare has positive early pivotal data for its second two-drug regimen for HIV, but more reassurance is needed on the relative rates of virologic suppression in patients with low and high viral loads, as well as on the long-term risk of virologic failure. The combination should help form ViiV's defense against rival Gilead and its new triple combination Biktarvy.
The Israel-based biopharma company said a Phase IIb trial of its oral treatment of non-alcoholic steatohepatitis hit the necessary endpoints to support a Phase III trial and FDA marketing application.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.